Ramius questions departure of Cypress director; Ark takes itself off the auction block; Somaxon inks drug sales pact with P&G

 @FierceBiotech: Eisai reports upbeat results from PhIII epilepsy study. Article | Follow @FierceBiotech

 @JohnCFierce: If a sitting president can't trump a federal judge on embryonic stem cell policy, I'll be very surprised. | Follow @JohnCFierce

> Ramius says it is suspicious about last week's resignation of an independent director of Cypress Bioscience, which has been resisting its offer of a buyout. "The very fact that Mr. (Jean-Pierre) Millon felt compelled to resign from the Board calls into serious question this Board's lack of true independence and balance," said Ramius Partner Managing Director Jeffrey Smith. "It seems clear to us that a director expressing a differing view was forced to relinquish his leadership role on the Board and subsequently chose to resign from the Board.  At best, this demonstrates an unhealthy board environment.  At worst, it is symptomatic of a truly dysfunctional board that continues to act without regard to the best interests of shareholders." Ramius release

> The UK's Ark Therapeutics says that it decided to end talks with various groups after none of them proffered a high enough offer for the developer. But Ark says it is still interested in finding a buyer for its wound care business. Story

> Somaxon has done a deal with P&G, positioning its insomnia drug Silenor for a September launch. Somaxon will pay a royalty on the sales revenue to P&G along with fees. Analysts have been skeptical about the potential of a new sleep drug in an already crowded marketplace. Story

> Emisphere Technologies is raising $7 million from a private placement. Emisphere release

> Renin emerges as a definitive marker for hypertension drugs. Report

> Researchers say that new acoustic cardiography technology could greatly improve the accuracy of detecting S3, an abnormal third sound in the heart's rhythm strongly associated with cardiac disease and heart failure. Article

> New studies will test preventive Alzheimer's therapies. Report

> The Medco Research Institute, the R&D arm of the giant pharmaceutical benefit manager, is mounting a clinical trial of a set of biomarkers from SureGene to determine whether variations in the markers can help guide the use of antipsychotic medicines. Article

And Finally... A new study has determined that people who suffer from migraine headaches run a higher risk of death from heart disease and strokes. Report

Suggested Articles

Paragon Biosciences has hired Kerensa Jimenez as the new CEO of its capital markets group Paragon Health Capital.

Regeneron has taken a step closer to getting a green light for its experimental high cholesterol drug as the FDA allows a swift review of evicanumab.

An analysis of Gilead’s remdesivir clinical trials found the studies “failed to provide equal representation of Black, Latinx and Native Americas."